Myasthenia gravis: Association of British Neurologists' management guidelines.
Pract Neurol
; 15(3): 199-206, 2015 Jun.
Article
en En
| MEDLINE
| ID: mdl-25977271
Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Manejo de la Enfermedad
/
Miastenia Gravis
/
Neurología
Tipo de estudio:
Guideline
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Pract Neurol
Año:
2015
Tipo del documento:
Article